Why Arena Pharmaceuticals Stock Is Getting Hammered Today

What happened

Shares of Arena Pharmaceuticals (NASDAQ: ARNA  ) , a small cap biotech, are down by more than 16% right Tuesday morning as the result of a $69 million public offering that was announced prior to the opening bell. According to the press release, the company also granted the underwriters a 30‑day option to purchase another 9 million shares of common stock.

A prescription bottle on top of some medical documents.

Image source: Getty Images.

So what

While it's never a great idea to tap the public markets for funds when your share price is dangerously close to the Nasdaq minimum bid of $1 per share, Arena didn't have much choice in this case. The company, after all, is facing a likely spike in its quarterly burn rate after deciding to pivot toward its clinical pipeline of early- to mid-stage candidates and move on from its first commercial product, Belviq. Compounding matters, Arena only had about $90 million in cash remaining, according to its last stated cash position.

Now what

Arena's strategy is to try to advance its experimental pulmonary arterial hypertension (PAH) drug, ralinepag, into a late-stage trial in an expedited manner. To do so, the drug needs to hit the mark in its ongoing mid-stage trial that's scheduled to produce a top-line data readout by mid-year. That said, ralinepag's value proposition ultimately revolves around it becoming a so-called "best-in-class" medicine within a rapidly maturing PAH market.

As that's a particularly tall order, especially for a company with rather limited resources like Arena, and investors may want to be extra cautious with this highly volatile biotech stock. That's not to say ralinepag -- or any of the biotech's other clinical candidates -- won't eventually strike gold in their clinical programs, but Arena doesn't have much room left for error at this point. 

10 stocks we like better than Arena Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Arena Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 3, 2017


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4014314, ~/Articles/ArticleHandler.aspx, 4/29/2017 7:11:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
Change down DOW 20940.5 -40.8 -0.2%
Change down S&P 500 2384.2 -4.6 -0.2%
Change down NASD 6047.6 -1.3 0.0%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/28/2017 4:00 PM
ARNA $1.34 Down -0.04 -2.90%
Arena Pharmaceutic… CAPS Rating: **

Article registration testing

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 63615239054033211442212866055243